ArticleEndocrine2026
Association of the combined triglyceride-glucose and frailty index with chronic kidney disease: evidence from two national cohort studies.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aimed to explore the relationships between TyG-Frailty Index (TyGFI), a comprehensive indicator of the triglyceride-glucose (TyG) index and frailty index (FI), and the risk of chronic kidney disease (CKD).
methodsA total of 8721 participants from the China Health and Retirement Longitudinal Study (CHARLS) and 9670 participants from the U.S. National Health and Nutrition Examination Survey (NHANES) were included for cross-sectional study; while 4102participants from CHARLS were included for longitudinal study. For longitudinal study, cumulative TyGFI (CumTyGFI) is calculated, and the participants were categorized into four clusters on the basis of the dynamic changes in the TyGFI through K-means clustering. Multivariable logistic regression models and cox proportional hazards models were applied to estimate associations with CKD, with adjustment for demographic, clinical, and lifestyle covariates. Restricted cubic spline (RCS) and subgroup analyses were used to explore dose-response relationships and interaction effects, respectively.
resultHigher TyGFI, older age, hypertension, diabetes, and dyslipidemia were associated with CKD. In fully adjusted models, the highest TyGFI quartile (CHARLS: OR 3.98, 95% CI 3.03-5.22; NHANES: OR 4.49, 95% CI 3.55-5.69), highest CumTyGFI quartile (HR 4.18, 95% CI 3.09-5.65), and "increasing TyGFI alteration" cluster (HR 3.56, 95% CI 2.69-4.71) all showed significant associations, with dose‑response trends confirmed by RCS.
conclusionIn two national datasets, higher TyGFI was associated with prevalent CKD in the cross-sectional analyses and with incident CKD in the longitudinal CHARLS analysis. TyGFI may serve as a compact epidemiological marker combining metabolic and frailty-related burden, although its predictive and clinical utility requires further validation.
Indexed as
Identifiers
42570033What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.